How J.D. was paid
$2.5M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Total |
|---|---|---|---|---|
| Shawn K. Singh, J.D.President, Chief Executive Officer and Director | $650,000 | $276,250 | $1,551,432 | $2,477,682 |
| Cynthia L. Anderson, CPAChief Financial Officer and Treasurer | $443,750 | $198,450 | $465,256 | $1,107,456 |
| Reid G. Adler, J.D.Chief Legal Officer | $450,000 | $198,450 | $527,357 | $1,175,807 |
| Joshua S. Prince, MBAChief Operating Officer | $410,000 | $183,015 | $465,235 | $1,058,250 |
What changed and why
- $2.5M$2,477,682: Singh’s Fiscal 2025 total compensation included $1,551,432 in option awards.
- $948K$947,917: Singh’s Fiscal 2024 total compensation was substantially lower than his Fiscal 2025 total.
- $500K$500,000: Singh received an option grant for this number of shares on June 24, 2024.
- $1.2M$1,175,807: Adler received the highest Fiscal 2025 total compensation among non-CEO named executives.
- 94%Over 94%: Votes cast supported the company’s 2024 say-on-pay proposal.
- $3.10$3.10: The Fiscal 2025 option awards’ fair value per share was determined using the Black-Scholes model.
Other Vistagen Therapeutics proxy statements
- 2026 proxy statement
Shawn K. Singh, J.D. paid $1.2M (-51% on the year).
Filed Jul 31, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.